Protocol Ledger

NCT07370207 · Phase II · RECRUITING

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

Interventional Phase II clinical trial protocol NCT07370207 sponsored by AusperBio Therapeutics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-06 Enrollment: 84 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07370207
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07370207
Protocol FieldVerified Registry Value
NCT IdentifierNCT07370207
Consolidated Lead SponsorAusperBio Therapeutics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment84 participants (ESTIMATED)
Registered Start Date2026-03-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07370207
Hospital Research SiteLocationSite Profile
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->
National Taiwan University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI